Pulse Brain · Growing Health Evidence Index
Peer-reviewed

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

Henry N. Ginsberg, Chris J. Packard, M. John Chapman, Jan Borén, Carlos A. Aguilar‐Salinas, Maurizio Averna, Brian A. Ference, Daniel Gaudet, Robert A. Hegele, Sander Kersten, Gary F. Lewis, Alice H. Lichtenstein, Philippe Moulin, Børge G. Nordestgaard, Alan T. Remaley, Bart Staels, Erik S.G. Stroes, Marja‐Riitta Taskinen, Lâle Tokgözoğlu, Anne Tybjærg‐Hansen, Jane K. Stock, Alberico L. Catapano

European Heart Journal · 2021

Read source ↗ All evidence

Summary

Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic stroke, and aortic valve stenosis. These data also indicate that TRL and their remnants may contribute significantly to residual cardiovascular risk in patients on optimized low-density lipoprotein (LDL)-lowering therapy. This statement critically appraises current understanding of the structure, function, and metabolism of TRL, and their pathophysiological role in atherosclerotic cardiovascular disease (ASCVD). Key points are (i) a working definition of normo- and hypertriglyceridaemic states and

Source type
Peer-reviewed study
DOI
10.1093/eurheartj/ehab551
Catalogue ID
SNmoj4435w-tnsfo7
Pulse AI · ask about this record

Dig deeper with Pulse AI.

Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.